500 Boylston Street, Boston, MA 02116 617-419-4700
Return to Results
The purpose of this study is to evaluate the long-term safety of Humira® in Adult Patients
with Chronic Plaque Psoriasis (Ps).
Ages:18 and older
Inclusion Criteria: 1. An adult patient (18 years of ago or older) with chronic plaque psoriasis who has been prescribed HUMIRA® therapy according to the local product labeling and meets one of the following criteria: - New initiated (within 4 weeks of registry entry) on HUMIRA® therapy; - Initiated HUMIRA® therapy in the past and: - Has received continuous (no more than 70 consecutive days off drug) HUMIRA® therapy and the physician can provide source documentation of SAEs, AEs, of Special Interest, and dosing information since initiation of therapy. OR - Is entering after participation in an Abbott HUMIRA (adalimumab) sponsored study and has received continuous (no more than 70 consecutive days off drug) HUMIRA® therapy after the completion of Abbott sponsored study and physician can provide source documentation of SAEs, AEs of Special Interest, and dosing information since initiation of commercial HUMIRA® (defined as a prescribed/non study drug). 2. Patient is willing to consent to data being collected and provided to Abbott; 3. Patient is capable of and willing to give written informed consent and to comply with the requirements of the registry. Exclusion Criteria: - Patient should not be enrolled if he/she cannot be treated in accordance with the local product label.
Trial ID: NCT00799877
Not Accepting Healthy Volunteers